Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 27.5% over the past six months, topping the S&P 500 by 16.2 percentage points.

ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.

Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to their estimated worth. Shareholders have seen the stock decline 73.6% over the past three years, which puts the current valuation in sharp focus for anyone still holding or looking at the company fresh. The recent announcement of a new growth plan, alongside higher revenue...

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Inspire Medical Systems’ second quarter results were marked by improved coding clarity and cost discipline, which management credited as key drivers behind the company’s outperformance versus Wall Street expectations. Despite a year-on-year revenue decline, CEO Tim Herbert pointed to effective navigation of the evolving reimbursement landscape as a critical factor, stating the company delivered “adjusted operating income and positive cash flow ahead of expectations through continued disciplined

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Revenue fell 7.6% on coding disruptions, but management raised full-year guidance.

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Moby summary of Inspire Medical Systems, Inc.'s Q2 2026 earnings call

Why Inspire Medical Systems stock moved on Q2 earnings and guidance Inspire Medical Systems (INSP) caught investor attention after Q2 results that topped revenue and earnings expectations despite a year over year decline tied to coding and reimbursement disruptions. The company raised its full year revenue and EPS guidance and introduced Project Horizon, a restructuring plan designed to free up about US$30 million for growth investment. The market responded positively to management’s...

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Despite a 7.6% revenue decline from coding disruptions, the company raises its full-year outlook and unveils Project Horizon to drive future growth.

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Inspire (INSP) delivered earnings and revenue surprises of +163.64% and +2.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 7.6% year on year to $200.6 million. The company’s full-year revenue guidance of $855 million at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $0.14 per share was significantly above analysts’ consensus estimates.

Medical technology company Inspire Medical Systems (NYSE:INSP) will be announcing earnings results this Monday after the bell. Here’s what to expect.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Butterfly Network (BFLY) delivered earnings and revenue surprises of +66.67% and +14.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

Inspire Medical's Inspire V rollout, broader approvals and clinical evidence support growth despite coding and reimbursement pressures.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.